GOSS: Gossamer Bio, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 346.70
Enterprise Value ($M) 515.53
Book Value ($M) 54.14
Book Value / Share 0.24
Price / Book 6.40
NCAV ($M) 47.52
NCAV / Share 0.21
Price / NCAV 7.30

Profitability (mra)
Return on Invested Capital (ROIC) -0.28
Return on Assets (ROA) -0.23
Return on Equity (ROE) -1.14

Liquidity (mrq)
Quick Ratio 6.74
Current Ratio 6.74

Balance Sheet (mrq) ($M)
Current Assets 344.27
Assets 350.88
Liabilities 296.74
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-12 13G/A Invus Global Management, LLC
02-05 13G Octagon Capital Advisors LP
01-30 13G/A Vanguard Group Inc
11-12 13G/A Fmr Llc 3.51 -35.29
2024-02-14 13G/A Hillhouse Capital Management, Ltd. 2.20
2024-02-09 13G/A ARCH Venture Fund IX, L.P.

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q – UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-12 10-Q – UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-07 10-Q – UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-03-05 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 302,858 1,535,617 19.72
2025-02-20 359,193 2,058,385 17.45
2025-02-19 330,477 2,206,099 14.98
2025-02-18 261,642 2,160,630 12.11

(click for more detail)

Similar Companies
GERN – Geron Corporation GILD – Gilead Sciences, Inc.
GLUE – Monte Rosa Therapeutics, Inc. HALO – Halozyme Therapeutics, Inc.
HLVX – HilleVax, Inc.


Financial data and stock pages provided by
Fintel.io